PRNewsWire
21 Aug 2026, 11:45 UTC · 1h ago
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
21 Aug 2026, 11:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AbbVie will present Phase 3 trial data for ABBV-706, an investigational SEZ6-targeted ADC, in relapsed/refractory small cell lung cancer. — Phase 3 results are critical catalysts for drug approval and potential new revenue streams in a high-unmet-need oncology segment.
+0.60AbbVie will present Phase 3 trial data for RC148 (ABBV-1480), a PD-1/VEGF bispecific antibody, used with chemotherapy in first-line squamous NSCLC. — First-line treatment data for a bispecific antibody represents a high-value market opportunity if efficacy is demonstrated.
+0.50AbbVie is presenting Phase 1b/2 study results for Telisotuzumab Adizutecan combined with a PD-1 inhibitor in untreated advanced non-squamous NSCLC. — Early-stage combination data provides a signal for pipeline viability but is less immediate than Phase 3 results.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
AbbVie will showcase preclinical data for Telisotuzumab vedotin in diffuse pleural mesothelioma. — Preclinical data suggests pipeline expansion but has low immediate impact on valuation compared to human clinical trials.
+0.10Which stocks this story touches
The company is showcasing innovation and positive progress across its lung cancer pipeline with several new data presentations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
